scholarly journals Changing the Prognosis of Metastatic Cervix Uteri Adenosquamous Carcinoma through a Multimodal Approach: A Case Report

2020 ◽  
Vol 13 (3) ◽  
pp. 1545-1551
Author(s):  
Mihai Teodor Georgescu ◽  
Dragos Eugen Georgescu ◽  
Teodor Florin Georgescu ◽  
Luiza Georgia Serbanescu
Keyword(s):  
Case Report ◽  
Adenosquamous Carcinoma ◽  
Treatment Approach ◽  
Complete Response ◽  
Team Work ◽  
Cervix Uteri ◽  
Multimodal Approach ◽  
Rare Cancer ◽  
Management Guidelines ◽  
Cancer Subtypes

Adenocarcinoma and adenosquamous carcinoma (AS) are 2 rare histological types of cervix uteri cancer constituting almost 20% of all cervix cancers, leading to a lack in patient management guidelines. We report the case of a 32-year-old woman with an oligometastatic cervix AS for which a multimodal treatment approach was used. Despite the patient’s bad prognosis, a complete response was achieved, which further resulted in excellent local control and prolonged survival. This case report serves the purpose of encouraging multidisciplinary team work and out-of-the-box thinking that should result in an individualized treatment for rare cancer subtypes.

scholarly journals Transoral Laser Surgery for Adenosquamous Carcinoma of the Glottis: First Case Report and Review of the Literature

2020 ◽  
pp. 014556132091657
Author(s):  
William Kendall ◽  
Panagiotis A. Dimitriadis ◽  
Fawzia Tahir ◽  
Sara Sionis
Keyword(s):  
Squamous Cell Carcinoma ◽  
Case Report ◽  
Laser Surgery ◽  
Poor Prognosis ◽  
Adenosquamous Carcinoma ◽  
Severe Dysplasia ◽  
Rare Cancer ◽  
Review Of The Literature ◽  
First Case ◽  
Disease Free

Adenosquamous carcinoma of the head and neck is a rare cancer associated with poor prognosis. Histologically, it is identified through the presence of both adenocarcinoma and squamous cell carcinoma, although it may be difficult to diagnose from initial endoscopic biopsies. We report a case of adenosquamous carcinoma of the glottis in an 82-year-old female patient who presented with progressive hoarseness of voice and in whom initial biopsies had shown only moderate to severe dysplasia. This is the first case in the literature of a primary adenosquamous carcinoma of the glottis managed successfully with a CO2 laser left type Va cordectomy. The patient remained disease-free 28 months postoperatively.

scholarly journals Long-term complete response in metastatic poorly-differentiated neuroendocrine rectal carcinoma with a multimodal approach: A case report

2021 ◽  
Vol 12 (6) ◽  
pp. 500-506
Author(s):  
Silvia Della Torre ◽  
Germana de Nucci ◽  
Pietro Maria Lombardi ◽  
Samuele Grandi ◽  
Gianpiero Manes ◽  
...  
Keyword(s):  
Case Report ◽  
Rectal Carcinoma ◽  
Complete Response ◽  
Multimodal Approach ◽  
Poorly Differentiated

Duvelisib as bridge to allotransplantation in refractory peripheral T-cell lymphoma with T-follicular helper phenotype: case report

2021 ◽  
pp. 030089162110272
Author(s):  
Ginevra Lolli ◽  
Beatrice Casadei ◽  
Cinzia Pellegrini ◽  
Lisa Argnani ◽  
Federica Cocito ◽  
...  
Keyword(s):  
Case Report ◽  
T Cell ◽  
Human Leukocyte ◽  
Complete Response ◽  
Unrelated Donor ◽  
Phosphatidylinositol 3 Kinase ◽  
Leukocyte Antigen ◽  
Follicular Helper ◽  
T Cell Lymphomas ◽  
T Cell Malignancies

Objective: Peripheral T-cell lymphomas (PTCLs) are a group of heterogeneous T-cell malignancies representing 5%–10% of aggressive lymphomas. The prognosis is poor for patients with relapsed/refractory (R/R) disease, with a median overall survival of less than 6 months and no standardized treatments. We discuss the role of the phosphatidylinositol 3-kinase (PI3K) γδ inhibitor duvelisib as bridge to allotransplantation in a patient with R/R PTCL. Methods: Case report. Results: A 55-year-old woman diagnosed with relapsed nodal PTCL with T-follicular helper phenotype received PI3K γδ inhibitor duvelisib in the context of the phase II PRIMO clinical trial. After two cycles at a dose of 75 mg twice daily, the patient achieved complete response (CR), which was subsequently consolidated with human leukocyte antigen fully matched unrelated donor allotransplantation. No major toxicities were recorded during the duvelisib treatment period or during hospitalization for allotransplantation. At the latest follow-up, the patient was alive and still in CR 10 months posttransplant. Conclusions: Duvelisib should be further explored as a bridge to allotransplantation in patients with R/R PTCL, given the success and low toxicity in our patient.

Sign in / Sign up

Export Citation Format

Share Document